How should ifosfamide be reconstituted, diluted, and administered intravenously?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ifosfamide Administration Guidelines

Ifosfamide should be reconstituted with 20 mL (for 1g vial) or 60 mL (for 3g vial) of Sterile Water for Injection to achieve a 50 mg/mL concentration, then diluted in 0.9% saline, 5% dextrose, or Lactated Ringer's to a final concentration of 0.6-20 mg/mL, and administered as a slow intravenous infusion over a minimum of 30 minutes 1.

Reconstitution Process

The FDA-approved preparation method is straightforward 1:

  • 1 gram vial: Add 20 mL of Sterile Water for Injection or Bacteriostatic Water for Injection
  • 3 gram vial: Add 60 mL of Sterile Water for Injection or Bacteriostatic Water for Injection
  • Shake to dissolve completely
  • Final concentration after reconstitution: 50 mg/mL

Dilution for Infusion

After reconstitution, further dilute the solution to achieve concentrations between 0.6-20 mg/mL using any of these compatible fluids 1:

  • 5% Dextrose Injection
  • 0.9% Sodium Chloride Injection (most commonly used)
  • Lactated Ringer's Injection
  • Sterile Water for Injection

Intermediate concentrations (e.g., 2.5% Dextrose, 0.45% Sodium Chloride, or combinations) are also acceptable based on stability data 1.

Administration Method

Infusion rate: Minimum 30 minutes for short infusions 1. The standard dosing is 1.2 g/m² per day for 5 consecutive days, repeated every 3 weeks 1.

Alternative Administration Schedules

For continuous infusion protocols, ifosfamide can be administered over 24 hours 2 or even extended to 7-day continuous infusions using ambulatory pumps 3. The drug remains stable for up to 9 days at temperatures up to 27°C, making prolonged infusions feasible 3.

Critical Safety Requirements

Mandatory Concurrent Mesna Administration

Mesna must always be given with ifosfamide to prevent hemorrhagic cystitis 4. The ASCO guidelines provide two acceptable regimens:

For short infusions (ifosfamide <2.5 g/m²/day):

  • Total daily mesna dose = 60% of total daily ifosfamide dose
  • Given as three bolus doses: 15 minutes before, then 4 hours after, then 8 hours after each ifosfamide dose 4

Alternative IV-oral regimen:

  • First dose: 20% of ifosfamide dose IV at time of ifosfamide administration
  • Second dose: 40% of ifosfamide dose orally at 2 hours post-ifosfamide
  • Third dose: 40% of ifosfamide dose orally at 6 hours post-ifosfamide
  • Total daily mesna = 100% of ifosfamide dose 4

For continuous infusions:

  • Mesna bolus: 20% of total ifosfamide dose
  • Followed by continuous mesna infusion: 40% of ifosfamide dose, continuing 12-24 hours after ifosfamide completion 4

Hydration Requirements

Extensive hydration is mandatory: minimum 2 liters of oral or intravenous fluid per day 1. This is non-negotiable for preventing bladder toxicity.

Stability and Storage

  • Refrigerate all constituted or diluted solutions 1
  • Use within 24 hours of preparation 1
  • Solutions are stable for 9 days at temperatures up to 27°C, but FDA labeling recommends the more conservative 24-hour timeframe 1, 3
  • Inspect visually for particulate matter and discoloration before administration 1

Common Pitfalls to Avoid

  1. Never administer ifosfamide without mesna - This is the most critical error that leads to severe hemorrhagic cystitis
  2. Do not infuse too rapidly - Minimum 30 minutes required; faster infusion increases toxicity risk
  3. Inadequate hydration - Must ensure at least 2L fluid daily throughout treatment
  4. Vomiting within 2 hours of oral mesna - Patient must repeat the oral dose or receive IV mesna instead 4
  5. Ignoring renal function - While specific dose adjustments aren't established, monitor closely in patients with compromised renal function 1

Practical Considerations

Outpatient administration is feasible and safe when proper protocols are followed 5. The transition to ambulatory settings has demonstrated cost savings without compromising safety, though neutropenic fever remains a risk requiring prompt management 5. Dose fractionation over 5 days (rather than single large doses) significantly reduces toxicity while maintaining efficacy 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.